Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada.

Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S, Rachlis A, Wobeser W, Macarthur RD, Binder L, Rosenes R, Loutfy MR.

HIV Clin Trials. 2011 Mar-Apr;12(2):89-103. doi: 10.1310/hct1202-89.

PMID:
21498152
2.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

3.

Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.

Soares LR, da Silva DC, Gonsalez CR, Batista FG, Fonseca LA, Duarte AJ, Casseb J.

Rev Inst Med Trop Sao Paulo. 2015 Mar-Apr;57(2):105-10. doi: 10.1590/S0036-46652015000200002.

4.

The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings.

Abrahams Z, Dave JA, Maartens G, Lesosky M, Levitt NS.

AIDS Res Ther. 2014 Aug 4;11:26. doi: 10.1186/1742-6405-11-26. eCollection 2014.

5.

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.

Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS.

Int J Epidemiol. 2002 Oct;31(5):1016-20.

6.

High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.

van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.

Trans R Soc Trop Med Hyg. 2007 Aug;101(8):793-8. Epub 2007 Apr 30.

PMID:
17467756
7.

Fat distribution in men with HIV infection.

Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):121-31.

8.

Fat distribution in women with HIV infection.

Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):562-71.

9.

Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.

Turcinov D, Stanley C, Rutherford GW, Novotny TE, Begovac J.

Eur J Epidemiol. 2009;24(5):267-74. doi: 10.1007/s10654-009-9330-2. Epub 2009 Mar 26.

10.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
11.

Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study.

Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH, Young M, Rubin N, Augenbraun M, Grunfeld C.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):461-6.

PMID:
14657755
12.

Magnetic resonance imaging evaluation of lipodystrophy in HIV-positive patients receiving highly active antiretroviral therapy.

Eichler K, Bickel TM, Klauke S, Eisen J, Vogl TJ, Zangos S.

Int J STD AIDS. 2015 Jul;26(8):582-9. doi: 10.1177/0956462414546916. Epub 2014 Aug 18.

PMID:
25139003
13.

Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.

Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):314-24. doi: 10.1097/QAI.0b013e31824330cb.

14.

HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Finkelstein JL, Gala P, Rochford R, Glesby MJ, Mehta S.

J Int AIDS Soc. 2015 Jan 15;18:19033. doi: 10.7448/IAS.18.1.19033. eCollection 2015. Review.

15.

Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.

Kalyanasundaram AP, Jacob SM, Hemalatha R, Sivakumar MR.

J Int Assoc Physicians AIDS Care (Chic). 2012 Sep-Oct;11(5):329-34. Epub 2011 Apr 20.

PMID:
21508297
16.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
17.

Stavudine versus zidovudine and the development of lipodystrophy.

Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, Goebel FD.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):237-44.

PMID:
11464142
18.

Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, Sirisanthana V.

Pediatr Infect Dis J. 2012 Apr;31(4):384-8. doi: 10.1097/INF.0b013e31823f0e11.

PMID:
22124211
19.
20.

Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy.

Crane HM, Grunfeld C, Harrington RD, Uldall KK, Ciechanowski PS, Kitahata MM.

HIV Med. 2008 Oct;9(9):780-6. doi: 10.1111/j.1468-1293.2008.00631.x. Epub 2008 Aug 27.

Items per page

Supplemental Content

Write to the Help Desk